Floatz logo

Tirzepatide

Overweight or Obesity; Type 2 Diabetes

Huazhong University of Science and Technologyprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Overweight or Obesity; Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
hrs9531
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1CC

Same molecule, other indications

Tirzepatide is also rated in:

type 1 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
psoriatic arthritisDormant
BBB
Indicative ·
74 / 100
View asset →
diastolic heart failureDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →